Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study of felzartamab for IgA ...

Global Cancer Antibody Drug Conjugates Market Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, Oct. 23, 2024 ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...

Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in ...

The initial program, dubbed Geneious Luma, aims to focus on monoclonal and multispecific antibodies. It will take the ability ...

Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

Donanemab, the most effective treatment yet for the disease, will be banned on the health service despite regulators ...

In recent months, the Delaware Court of Chancery has decided four significant cases regarding merger agreement earnout provisions. Most notably, ...

Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...

Its lead candidate, CDX-0159 (barzolvolimab), is a monoclonal antibody that inhibits KIT receptor signaling, which is important in mast cell-driven disorders. Positive results from clinical trials ...